Patients with uncontrolled essential hypertension have elevated concentrations of superoxide anion (O 2 ÀK ), hydrogen peroxide (H 2 O 2 ), lipid peroxides, endothelin, and transforming growth factor-b (TGF-b) with a simultaneous decrease in endothelial nitric oxide (eNO), superoxide dismutase (SOD), vitamin E, and long-chain polyunsaturated fatty acids (LCPUFAs). Physiological concentrations of angiotensin II activate NAD(P)H oxidase and trigger free radical generation (especially that of O 2 ÀK ). Normally, angiotensin II-induced oxidative stress is abrogated by adequate production and release of eNO, which quenches O 2 ÀK to restore normotension. Angiotensin II also stimulates the production of endothelin and TGF-b. TGF-b enhances NO generation, which in turn suppresses TGF-b production. Thus, NO has a regulatory role on TGF-b production and is also a physiological antagonist of endothelin. Antihypertensive drugs suppress the production of O 2 ÀK and TGF-b and enhance eNO synthesis to bring about their beneficial actions. LCPUFAs suppress angiotensin-converting enzyme (ACE) activity, reduce angiotensin II formation, enhance eNO generation, and suppress TGF-b expression. Perinatal supplementation of LCPUFAs decreases insulin resistance and prevents the development of hypertension in adult life, whereas deficiency of LCPUFAs in the perinatal period results in raised blood pressure later in life. Patients with essential hypertension have low concentrations of various LCPUFAs in their plasma phospholipid fraction. Based on this, it is proposed that LCPUFAs serve as endogenous regulators of ACE activity, O 2 ÀK , eNO generation, and TGF-b expression. Further, LCPUFAs have actions similar to statins, inhibit (especially o-3 fatty acids) cyclooxygenase activity and suppress the synthesis of proinflammatory cytokines, and activate the parasympathetic nervous system, all actions that reduce the risk of major vascular events. Hence, it is proposed that availability of adequate amounts of LCPUFAs during the critical periods of growth prevents the development of hypertension in adulthood.
Introduction
Essential or primary hypertension affects about 20-25% of all adults above the age of 45-50 years. Hypertension is common in overweight and obese subjects. The importance of hypertension lies in the fact that it forms one of the main risk factors for coronary heart disease (CHD), stroke, atheroslcerosis, and peripheral vascular disease (PVD).
Hypertension is characterized by an increase in peripheral vascular resistance. This is attributed to the loss or decrease in endothelium-dependent vasodilation. Endothelium produces vasoactive factors such as prostacyclin (PGI 2 ), nitric oxide (NO), endothelium-derived hyperpolarizing factor (EHF), endothelin, and prostaglandin E 1 (PGE 1 ) (Kumar & Das, 1993) . Under normal conditions, there is a balance between vasoconstrictors and vasodilators such that normal blood pressure is maintained. When this balance is tilted more in favor of vasoconstrictors such as endothelins or when the concentrations of vasodilators are reduced, hypertension will set in.
Free radicals, NO, and PGI 2 in hypertension Reduced production or decreased half-life of NO and/or increased production of superoxide anion (O 2 ÀK ) promotes endothelial dysfunction, increases peripheral vascular resistance, and eventually elevates blood pressure (Kumar & Das, 1993) . One mechanism by which endotheliumdependent vasodilation is impaired is an increase in the oxidative stress that inactivates NO and PGI 2 (Kumar & Das, 1993) .
We observed that in patients with uncontrolled essential hypertension, O 2 ÀK , hydrogen peroxide (H 2 O 2 ), and lipid peroxides were produced in significantly large amounts, which reverted to normalcy following the control of hypertension by antihypertensive drugs (Suryaprabha et al, 1990; Kumar & Das, 1993) . Free radicals, especially O 2 ÀK , modulate the tone of vascular smooth muscles directly by acting on the smooth muscle cells. O 2 ÀK also reduces the halflife of PGI 2 and NO, thereby enhancing peripheral vascular resistance and increase in blood pressure (Kumar & Das, 1993) . Thus, O 2 ÀK could be an endothelial-derived vasoconstrictor (Katusic & Vanhoutte, 1989) . A significant decrease in the levels of superoxide dismutase (SOD) and vitamin E is seen in subjects with uncontrolled hypertension (Kumar & Das, 1993; Jun et al, 1996) . The concentrations of SOD also reverted to normalcy following the control of hypertension (Kumar & Das, 1993) . In both animals and humans, SOD activity decreases with age (Nakazono et al, 1991; Hamilton et al, 2001) . Wistar-Kyoto (WKY) and stroke-prone spontaneously hypertensive rats (SHRSP) showed decreased NO bioavailability and increased O 2 ÀK generation with age. This was found to be related to enhanced NAD(P)H oxidase activity (Hamilton et al, 2001 ). The role of O 2 ÀK in hypertension received further impetus from the observation that a fusion protein (HB-SOD) consisting of human Cu-Zn-type SOD and a C-terminal basic peptide with a high affinity for heparan sulfate on endothelial cells not only localized to the vascular walls but also prevented the development of hypertension in the spontaneously hypertensive rats (SHR) (Nakazono et al, 2001) . The role of O 2 ÀK in hypertension is not without controversy. For instance, simvastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, used in the management of hyperlipidemias is known to behave like an anti-oxidant: simvastatin increases the activities of SOD and glutathione peroxidase and thus improves endothelial function (Carneado et al, 2002) . No reduction in the increased blood pressure was noted in simvastatin-treated SHR, and subjects with hypertension, suggesting that O 2 ÀK may not always be responsible for hypertension. In several of these animal and human studies (Carneado et al, 2002) , concentrations of NO were not measured. It is likely that failure of simvastatin to restore the concentrations of NO to normalcy could explain their inability to reduce hypertension. Sprague-Dawley rats when chronically fed 10% glucose drinking solution along with normal chow showed elevated systolic blood pressure, aortic basal O 2 ÀK production, plasma levels of insulin and glucose, as well as an insulin resistance index (El Midaoui et al, 2002) . Simultaneous treatment with aspirin attenuated these abnormalities. Chronic in vivo treatment with aspirin prevented the increase in O 2 ÀK production (El Midaoui et al, 2002) . Aspirin also preferentially blocks the synthesis of thromboxane A 2 (TXA 2 ) from its precursor arachidonic acid without interfering with the synthesis of PGI 2 , a potent vasodilator and platelet antiaggregator. It is likely that the ability of aspirin not to interfere with the synthesis of PGI 2 and its ability to enhance NO production and/or its half-life by decreasing oxidative stress could be responsible for its beneficial actions. These results (Carneado et al, 2002; El Midaoui et al, 2002) suggest that the balance between O 2 ÀK , NO, and PGI 2 is critical in the prevention of hypertension.
Increase in O 2
ÀK production in hypertension: but, how and why? NAD(P)H oxidase is the source of O 2 ÀK in vascular cells.
Enhanced O 2 ÀK generation in hypertension is caused by the activation of vascular NAD(P)H oxidase (Zalba et al, 2001) . Using reverse transcription-polymerase chain reaction and Western blotting, Chabrashvili et al (2002) showed the presence of mRNA for five subunits of phagocyte NAD(P)H oxidase, and also for MOX1 and RENOX (NOX4) in adult rat kidney. P47phox, p67phox, and p22phox, subunits of NAD(P)H oxidase, were also demonstrated in the vasculature, macula densa, distal convoluted tubule, cortical collecting duct, and outer and inner medullary ducts of the kidney. An increase in the mRNA, and protein of p47phox in the vasculature, macula densa, and distal nephron was reported in the young prehypertensive SHR. Kidneys of adult SHR also had a significantly greater mRNA for p47phox. A 10-fold upregulation of vascular NAD(P)H oxidase with a three-fold increased production of O 2 ÀK and a concomitant impairment of the NO signal transduction pathway was observed in hypertension (Morawietz et al, 2001) . Studies conducted on animals and human subjects showed that angiotensin II stimulated free radical generation by upregulating several subunits of membrane-bound NAD(P)H oxidases (Kumar & Das, 1993; Zhang et al, 1999; Wolf, 2000) . Further, chronic inhibition of NO synthesis in rats increased aortic O 2 ÀK production, and redox-sensitive transcription factors NF-kB and AP-1 (Kitamoto et al, 2000) . (Touyz & Schiffrin, 2001) . Angiotensin II-stimulated PLD activity and DNA and protein synthesis were significantly higher in vascular smooth muscle cells from hypertensives than normotensives, indicating that increased activation of PLDdependent pathways is responsible for enhanced oxidative stress in essential hypertension. Competitive inhibition of the NAD(P)H oxidase assembly completely inhibited O 2 ÀK production and attenuated angiotensin II-induced blood pressure elevation in experimental animals. This suggests that NAD(P)H oxidase assembly occurs de novo in vivo (Rey et al, 2001) . Activation of NAD(P)H oxidase is seen not only in SHR, and patients with essential hypertension but also in mineralocorticoid (deoxycorticosterone acetate, DOCA,-salt) hypertensive rats (Beswick et al, 2001) . Thus, NAD(P)H oxidase activation could be a general mechanism by which hypertension develops irrespective of the mode of induction of hypertension.
How O 2 ÀK induces hypertension
Normally there is a balance between the steady-state level of NO and O 2 ÀK in the vessel (Somers & Harrison, 1999 (Guzik et al, 2002) . Since NO and PGI 2 are potent vasodilators and platelet antiaggregators, their oxidative inactivation by O 2 ÀK leads to an increase in peripheral vascular resistance and development of hypertension (Kumar & Das, 1993) . Endothelial cells also produce endothelin, a potent vasoconstrictor and a physiological antagonist of NO. Exposure of cultured human umbilical vein endothelial cells and coronary artery smooth muscle cells to O 2 ÀK increased preproendothelin-1 promoter activity, endothelin-1 mRNA synthesis, and big endothelin-1 expression (Kaehler et al, 2002) . Conversely, exposure of endothelial cells to NO reduced the levels of mRNA for preproendothelin-1 (Smith et al, 2002 Studies in human subjects suggested that the selective defect in NO synthesis is present in hypertension, which could be responsible for the impaired endothelium-dependent vasodilatation seen. Vasodilator response to acetylcholine (which stimulates NO release from endothelial cells) was significantly reduced in humans with hypertension compared to normotensives (Cardillo et al, 1998) . On the other hand, vasodilator response to isoproterenol (a b-receptor agonist that stimulates NO synthesis by increasing intracellular cAMP) and sodium nitroprusside, a NO donor, was similar in normotensives and hypertensives, indicating that the endothelial dysfunction in essential hypertension is because of selective abnormality of NO synthesis. Endothelium-dependent vasodilation to acetylcholine (which is dependent on eNOS) declines and oxidative stress increases with aging ). This explains why hypertension is common with advancing age.
In platelets of hypertensive patients, NO levels were significantly lower and cytosolic Ca 2 þ levels were higher compared to normotensives (Camilletti et al, 2001) . This inverse correlation between platelet NO and cytosolic Ca 2 þ levels explains the link between hypertension and altered platelet function in hypertension and indicates a role for NO in cardiovascular events (Camilletti et al, 2001 ). Thus, NO abnormality is not localized to the vascular endothelium but may occur in several other tissues as well. Studies in animals and humans revealed that chronic inhibition of NO induces hypertension. Oral L-N G -nitro-Larginine, an NOS inhibitor, not only elevated blood pressure in rats but also decreased the plasma level of NO and increased peripheral vascular resistance (Takahashi et al, 1995) . SHR are significantly less sensitive to hypotensive effects of NO donors (Stys et al, 1998) unlike humans (Cardillo et al, 1998) . Healthy humans, when infused with N G -monomethyl-L-arginine (L-NMMA), an inhibitor of NOS, showed increased mean arterial pressure, decreased heart rate, decreased cardiac index, increased total peripheral resistance, and urinary sodium and fractional sodium excretions with no change in creatinine clearance (Haynes et al, 1993) . These data suggest that basal generation of NO plays a role in the maintenance of peripheral vascular resistance and normal blood pressure. Vasodilator response to NO donors was similar in normotensives and hypertensives (Cardillo et al, 1998) whereas SHR were less responsive to NO donors (Stys et al, 1998) . This suggests that SHR were differently sensitive to NO donors compared to hypertensive subjects, which in part could be attributed to a difference in the species (humans vs animals).
In this context, the relation between L-arginine, asymmetrical dimethylarginine (ADMA), and NO with particular reference to endothelial dysfunction needs special emphasis. A high occurrence of cardiovascular complications in subjects who had higher plasma ADMA concentrations has been described (see section on ADMA in hypertension). ADMA is an endogenous competitive inhibitor of eNOS and thus contributes to endothelial dysfunction. L-Arginine supplementation improves endothelial dysfunction in patients with end-stage renal disease and CHD by competing with ADMA and improving NO synthesis. These data once again support the importance of NO in CHD and other vascular diseases.
Minerals, cyclosporine, hypertension, and NO NO is synthesized within the kidney and plays a significant role in the regulation of renal hemodynamics and excretory function. Bradykinin and acetylcholine induce vasodilation by increasing NO synthesis, and thus enhance diuresis and natriuresis. NO released from macula densa can affect afferent arteriolar constriction. Inhibition of NO synthesis decreases renal blood flow and sodium excretion (Bachmann & Mundel, 1994) , partly due to an interaction between NO and the renin-angiotensin system. Thus, NO modulates sodium excretion by inducing changes in renal arterial pressure without any effect on renal autoregulation, indicating a role for NO in pressure natriuresis. NO produced in the proximal tubule influences the effects of angiotensin on tubular reabsorption and in the collecting duct, and thus alters solute transport. Similarly, NO has an active role in the glomerulus (Bachmann & Mundel, 1994) . In pathological conditions such as glomerulonephritis, infiltrating macrophages produce iNO and this, in turn, may have a role in proteinuria and mesangial proliferation.
In hypertensive subjects, a high salt diet (20-23 g/day) induced an increase in blood pressure, decreased plasma nitrate plus nitrite, and enhanced ADMA concentrations. These abnormalities reverted to normalcy following salt restriction. Alterations in plasma nitrite and nitrate levels correlated inversely with blood pressure and plasma ADMA levels after salt loading and salt restriction (Fujiwara et al, 2000) , suggesting that salt intake modulates NO synthesis via changes in ADMA concentrations. ADMA blocks NO synthesis, which could explain, in part, the role of salt in human hypertension. Cyclosporine induces endothelial dysfunction. In animals, subcutaneous injections of cyclosporine impaired vascular response to acetylcholine, which were normalized by pretreatment with SOD (Diederich et al, 1994) . Thus, even cyclosporine-induced endothelial dysfunction and hypertension can be related to increased O 2 ÀK generation and simultaneously decreased NO generation. Cyclosporine-treated rats also showed increased mRNA expression of preproendothelin-1, decreased endothelial NOS both in the aorta and the renal cortex, and an upregulation of the endothelin-converting enzyme 1 mRNA expression in the renal cortex with a significantly increased protein content and enzyme activity (Gonzalez-Santiago et al, 2000) . These changes are in agreement with the concept that hypertension is caused by an imbalance in the O 2 À K /NO system and an enhanced production of endothelin. Dietary calcium reduces blood pressure by stabilizing the arterial membranes, blocking its own entry into the cell, inhibiting contraction of arterial smooth muscles and by enhancing NO synthesis (Passmore et al, 1997; Das, 2001a) . Conversely, high salt intake reduces NO synthesis, although this action has been disputed (Schmidt et al, 2001) . High salt intake initially stimulates NO production (to maintain normotension despite increase in blood volume caused by increased salt intake) to maintain blood flow, and only when the enhanced salt intake continues for a long time, NO synthesis is decreased (possibly because of the exhaustion of the eNOS activity), which leads to the development of hypertension (Nakanishi et al, 2002) . On the other hand, supplementation of L-arginine reduces high salt intakeinduced hypertension (Campese et al, 1997; Bayorh et al, 1999) . Vasodilation to acetylcholine increases with potassium chloride supplementation, in patients with hypertension (Taddei et al, 1994) , which explains its mild to moderate antihypertensive action. Based on this, I proposed earlier that optimum physiologic concentrations of sodium, potassium, calcium, and magnesium enhance the synthesis and release of NO, PGE 1 , and PGI 2 , known vasodilators and platelet antiaggregators, to maintain normal blood pressure (Das, 2001a) . Even vitamin C reverses impaired endothelial vasodilation by enhancing NO, PGI 2 , and PGE 1 generation and blocking O 2 ÀK production (Das, 1985 (Das, , 2000a (Das, , 2001a Taddei et al, 1998) .
ADMA in hypertension
One endogenous factor that inhibits NO synthesis is ADMA.
There is now strong evidence to suggest that increased plasma ADMA concentrations prospectively determine cardiovascular and overall mortality in patients with end-stage renal disease. A strong association between ADMA concentration in serum with risk of acute coronary events has been described. Endothelial dysfunction in hypercholesterolemic individuals can be related to plasma concentrations of ADMA (Boger et al, 1998) . Plasma ADMA is a strong and independent predictor of overall mortality and cardiovascular outcome in hemodialysis patients (Zoccali et al, 2001) . Both in hypertension and pre-eclampsia, the plasma concentrations of ADMA were found to be high (Surdacki et al, 1999; Vallance, 2001) . Increased serum concentrations of ADMA were associated with an increased risk of acute coronary events indicating that endothelial dysfunction occurs in CHD (Valkonen et al, 2001) . Endothelial dysfunction seen in the offspring of patients with essential hypertension was found to be caused by impaired basal production of NO, which could be restored to normalcy by intrabrachial L-arginine (Taddei et al, 1996; McAllister et al, 1999) . This suggests that impairment in NO production precedes the onset of hypertension.
Antihypertensive drugs suppress O 2 ÀK and enhance NO Reduction in blood pressure by lisinopril, an ACE inhibitor, was found to be associated with increased plasma NO and 6-keto-PGF 1a (Kohno et al, 1999) . Benidipine, a calcium antagonist, or trandolapril, an ACE inhibitor, decreased blood pressure, and normalized NO and cGMP levels (Takase et al, 2000) . Others also reported similar results (Jain et al, 2001; Delles et al, 2002; . These data indicate that various antihypertensive drugs increase NO and PGI 2 formation. Earlier, we showed that NO is a potent inhibitor of ACE activity (Kumar & Das, 1997) and that calcium antagonists and b-blockers block free radical generation and lipid peroxidation process (Kumar & Das, 1993) . Thus, antihypertensive drugs inhibit O 2 ÀK generation, which in turn increases the half-life of NO and also enhances NO production. On the other hand, NO inhibits ACE activity whereas angiotensin II enhances O 2 ÀK generation by stimulating NAD(P)H oxidase. Thus, a close interaction exists between NO, O 2
ÀK
, ACE activity, angiotensin II, and the regulation of blood pressure (see Figure 1 ).
Transforming growth factor-b, NO, and hypertension
Recently, circulating levels of transforming growth factor-b (TGF-b) were found to be elevated in hypertensives compared with normotensives (Suthanthiran et al, 2000; Derhaschnig et al, 2002) . Both systolic and diastolic blood pressure was significantly higher in individuals with the CC genotype of TGF-b (869T-C) compared to those with the TT or TC genotype, suggesting that the TGF-b1 gene could be a candidate susceptibility locus for hypertension (Yamada et al, 2002) . Elevated plasma TGF-b concentrations were noted in patients with albuminuria in hypertension and diabetic nephropathy, whereas angiotensin receptor blockers and ACE inhibitors decreased its excretion. This indicates that hyperexpression of TGF-b is an indicator of promotion of vascular and renal disease (Esmatjes et al, 2001; Wong et al, 2001; Agarwal et al, 2002; Houlihan et al, 2002; Russo et al, 2002) . Angiotensin II cooperates with endothelin and TGF-b to activate collagen type I gene, resulting in the increased formation of extracellular matrix protein in the renal cortex and aorta (Fakhouri et al, 2001) . This can lead to renal scarring and end-stage renal disease in patients with hypertension and diabetes mellitus. On the other hand, chronic anti-TGF-b antibody reduced blood pressure, proteinuria, and the degree of glomerulosclerosis and renal medullary fibrosis in Dahl salt-sensitive rats (Dhaly et al, 2002) . In vitro studies revealed that neutralizing TGF-b could inhibit increased synthesis of collagen by cultured mesangial cells in the presence of high glucose. This suggests that TGFb enhances collagen synthesis (Riser et al, 1998) . Angiotensin II, high salt diet, and cyclosporine stimulate TGF-b expression in the kidney and endothelium (Shin et al, 1998; Wolf, 1998; Ying & Sanders, 1999) . Both high salt intake and high glucose also enhance NO synthesis (Ying & Sanders, 1999; Trachtman et al, 1998) , whereas NO blocks TGF-b synthesis and suppresses matrix protein synthesis by mesangial cells (Craven et al, 1997; Studer et al, 1999) . Conversely, TGF-b inhibits NO synthesis in mesangial cells (Koide et al, 1994; Lagadec et al, 1999) . However, in skeletal muscle and endothelial cells, TGF-b enhanced NO synthesis. This indicates that the regulation of NO production by TGF-b may depend on the cell type studied (Inoue et al, 1995; Williams et al, 1996) . Nevertheless, this suggests that an interaction exists between TGF-b and NO.
High salt, high glucose, and cyclosporine also enhance O 2 ÀK generation by stimulating NAD(P)H oxidase activity, augment endothelin and TGF-b synthesis, and enhance ACE activity (which leads to increased formation of angiotensin II), events that increase blood pressure and cause damage to target organs. In view of this, the enhanced formation of NO in response to high salt intake and glucose concentrations could be considered as a compensatory mechanism to blunt the actions of angiotensin II, endothelin, and TGF-b since NO inhibits ACE activity, quenches O 2 ÀK , antagonizes the vasoactive actions of angiotensin II, and reduces the production of TGF-b. Thus, NO plays a vital role in the regulation of blood pressure and prevention of hypertension. In this context, it is interesting to note that longchain polyunsaturated fatty acids (LCPUFAs) regulate NO synthesis.
LCPUFAs as endogenous antihypertensive agents
Dietary linoleic acid (LA, 18:2 o-6) is converted to gammalinolenic acid (GLA, 18:3 o-6) and dihomo-GLA (DGLA, 20:3 o-6) by specific enzymes that are controlled by genetic, hormonal, and nutritional factors (Das, 1985 (Das, , 1988 (Das, , 1991 (Das, , 1999 (Das, , 2001a . Saturated and trans-fatty acids interfere with the formation of vasodilator prostaglandins (PGs), PGE 1 and PGI 2 , elevate blood pressure, and exacerbate spontaneous hypertension (reviewed in Das, 2001a) . LA and DGLA enhance the formation of these vasodilator PGs and prevent an increase in blood pressure induced by the feeding of saturated fats (Das, 2001a) . Fish oil, a rich source of o-3 fatty acidsFeicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6)Freduces blood viscosity and lowers blood pressure (reviewed in Das, 2000b Das, , 2001a . EPA and DHA inhibit the formation of TXA 2 , a potent vasoconstrictor and platelet aggregator, and enhance that of PGI 3 , a vasodilator and platelet antiaggregator. In addition, EPA lowers the tissue levels of AA and enhances those of DGLA, the precursor of PGE 1 (Das, 1987 (Das, , 2000b . Hence, when adequate amounts of o-3 and o-6 fatty acids are provided, blood pressure remains normal.
LCPUFAs not only enhance the formation of the beneficial PGs but also inhibit ACE activity (Kumar & Das, 1997; Das, 1997; Das, 2001a) and augment the synthesis of eNO (McVeigh et al, 1993) . On the other hand, there is evidence to suggest that the L-arginine-NO system could upregulate the metabolism of LCPUFAs in experimental animals (Mohan & Das, 2000 . Hence, it is reasonable to assume that whenever the concentrations of LCPUFAs are low, the synthesis and release of NO will also be low, and vice versa. Since endothelial cells are the major source of NO, the LCPUFA content of endothelial cells likely affects the synthesis and release of NO, which explains why supplementation of AA, EPA, and DHA enhances the synthesis of NO (Das, 2001a) . In patients with hypertension, the plasma concentrations of LA, AA, and DHA were found to be low (Das, 1995 (Das, , 2001a . Following control of hypertension with calcium antagonists, b-blockers, and ACE inhibitors, the concentrations of NO and O 2 ÀK reverted to normalcy (Kohno et al, 1999; Takase et al, 2000; Jain et al, 2001; Delles et al, 2002; , whereas those of LCPUFAs remained low (Das, 2001a) . This suggests that abnormalities in NO, O 2
ÀK
, and LCPUFAs in hypertension are closely associated with each other.
In this context, it is important to note that normal Asian Indians, in whom insulin resistance and hypertension are common, have significantly lower concentrations of AA, EPA, and DHA than normal, healthy Canadians and Americans in their plasma phospholipids . LCPUFAs suppress the synthesis of tumor necrosis factor-a (TNF-a) and other proinflammatory cytokines Das, 2002a) . Healthy Indian Asians had higher C-reactive protein, a marker of systemic inflammation, than Europeans and also may have higher levels of TNF-a, which may explain the higher incidence of insulin resistance and other features of metabolic syndrome X including hypertension in them (Das, 2002a, b) . Weisinger et al (2001) reported that DHA deficiency in the perinatal period can raise blood pressure later in life, even when animals were subsequently replete with this fatty acid. Animals raised on an LCPUFAdeficient diet drank less water and ingested more sodium, features that are somewhat similar to high salt intakeinduced hypertension. But it is not known whether these LCPUFA-deficient animals had any abnormalities in the NO-O 2 ÀK system.
Breast milk consumption has been associated with lower blood pressure in later life (Taittonen et al, 1996; Wilson et al, 1998; Singhal et al, 2001) . I attributed this beneficial action to the presence of significant amounts of LCPUFAs in human milk (Das, 2001c) . Breast-fed infants had a significantly higher percentage of LCPUFAs in their tissues compared with those of the formula-fed group (Baur et al, 1998) , lending support to this suggestion.
Both EPA and DHA inhibited the development of proteinuria and suppressed hypertension in stroke-prone SHR, and prevented the exaggerated growth of vascular smooth muscle cells from these animals by suppressing the synthesis of TGF-b (Nakayama et al, 1999; Miyazaki et al, 2000) . LCPUFAs also interact with other nutrients and the Larginine-NO-O 2 ÀK system, suppress ACE, and lower blood pressure (Das, 1985 (Das, , 2001a Mohan & Das, 2000 ; see Figure 1 ).
Conclusion
Blood pressure is controlled by genetic, hormonal, and nutritional factors. In a genetically predisposed individual, hypertension could be precipitated by either hormonal or nutritional factors. Dietary salt, calcium, antihypertensive drugs, angiotensin II, and cyclosporine interact with the NO-O 2 ÀK system, and thus either enhance or reduce blood pressure. LCPUFAs enhance eNO synthesis and suppress the production of TGF-b. NO is not only a potent vasodilator but also suppresses TGF-b production. Thus, both NO and LCPUFAs modulate the synthesis and actions of TGF-b in addition to interacting with each other. This interaction between various factors/molecules is not only interesting but also suggests that the pathobiology of hypertension is complex (see Figure 1 ). In addition, LCPUFAs have actions similar to HMG-CoA reductase inhibitors, statins, and may mediate some of the beneficial actions of statins (Das, 2001d) . I suggested that o-3 fatty acids in addition to their ability to suppress the production of proinflammatory cytokines can enhance brain acetylcholine levels and parasympathetic tone, resulting in an increase in heart rate variability and, hence, protection from malignant ventricular arrhythmias (reviewed in Das, 2001e) , the major cause of death from CHD. It is not yet clear what initial event triggers the development of hypertension. High dietary intake of saturated and trans-fats, as is the custom with the present American and Western diet, reduces the formation of vasodilator PGs and elevates blood pressure (Das, 2001a) . Saturated and trans-fats also interfere with the metabolism of LCPUFAs. This, in turn, may reduce the formation of eNO and initiate the development of hypertension (McCarron et al, 1984; Das, 2000b Das, , 2001c Das, , f, 2002b . If this is true, it suggests that perinatal supplementation of LCPUFAs will prevent or postpone the development of hypertension in adult life (Das, 2001c (Das, , 2002c Weisinger et al, 2001) . Since LCPUFAs are also essential for both somatic and brain growth and development of the fetus and the newborn, and have several other important physiological actions in various tissues, organs, and systems (Das, 2002c) , it is worthwhile to explore the possibility that perinatal supplementation of LCPUFAs can indeed prevent hypertension in adult life.
